Trial Profile
Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2016 Results published in the Annals of Allergy, Asthma and Immunology